Recessive dystrophic epidermolysis bullosa is a severe inherited blistering skin disorder caused by biallelic COL7A1 mutations, resulting in fragility of skin and mucous membranes with chronic wounds and scarring.
INmune Bio will present new Phase III clinical data for its CORDStrom cell therapy for recessive dystrophic epidermolysis bullosa. The webinar on February 26, 2026, will feature investigators discussing outcomes including skin score improvements and quality-of-life measures. CORDStrom represents a systemic, disease-modifying alternative to topical treatments for this rare skin disorder.
INmune Bio announced FDA alignment on Phase III registration program for XPro1595 in Alzheimer's disease and submitted regulatory packages for CORDStrom in rare disease treatment, marking key milestones toward commercialization.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07700966 |
A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting |
RECRUITING | |
| NCT07684105 |
Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis / Necker (EBUDE Study) |
NOT_YET_RECRUITING | NA |
| NCT07193134 |
GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment |
RECRUITING | PHASE1/PHASE2 |
| NCT07016750 |
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa |
RECRUITING | PHASE3 |
| NCT07011589 |
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT06834035 |
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa |
RECRUITING | PHASE1/PHASE2 |
| NCT06713434 |
Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05944250 |
A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients |
COMPLETED | NA |
| NCT05725018 |
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05143190 |
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01) |
COMPLETED | PHASE2 |
